Companies

Cipla gets USFDA nod for drug to treat rare genetic condition angioedema

PTI New Delhi | Updated on July 14, 2020 Published on July 14, 2020

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Icatibant Injectable, indicated for treatment of acute attacks of hereditary angioedema - a rare genetic condition - in adults.

Cipla’s Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire’s Firazyr, the company said in a regulatory filing.

The firm said “it has received final approval for its abbreviated new drug application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration”.

Quoting IQVIA (IMS Health) data, Cipla said Firazyr and its generic equivalents had US sales of approximately $270 million for the 12-month period ending May 2020.

Shares of Cipla were down 0.93 per cent to ₹632.20 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 14, 2020
This article is closed for comments.
Please Email the Editor